ESMO Breast 2022 | The use of the Ki-67 in deciding which patients with HR+ breast cancer can safely avoid chemotherapy

Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, Korea, talks on the use of the Ki-67 score in patients with HR-positive breast cancer to optimize the decision making on who can benefit from endocrine treatment and avoid chemotherapy. This interview took place at the European Society for Medical Oncology (ESMO) Breast Cancer 2022 congress in Berlin, Germany.